论文部分内容阅读
研究丁丙诺啡口含片对晚期癌痛的镇痛作用。方法：72例经病理或细胞学确诊的中晚期癌症患者，采用多中心开放试验。其中51例给丁丙诺啡口含片0．6～1．2mg／d，tid，舌下合化；21例为1．2～2．4mg／d，按q8h或q6h舌下合化。资料数据采用t检验及x~2检验作统计学处理。结果：72的丁丙诺啡口含片开放试验，临床镇痛总有效率、显效率及有效率分别为91．67％、86．11％及5．56％。21例大剂量组镇痛效果优于小剂量组；对骨转移癌镇痛效果欠佳。主要不良反应为思睡、头晕、恶心、呕吐和头痛；2周内未发现药物耐受或身体依赖现象。结论：丁丙诺啡口合片对晚期癌痛确有明显镇痛效果，药效维持时间长，且使用方便，不良反应轻、成瘾性小、患者容易接受，国内有开发价值。
To study the analgesic effect of buprenorphine buccal tablets on advanced cancer pain. METHODS: Seventy-two patients with advanced-stage cancer diagnosed by pathology or cytology underwent multi-center open trials. Of these, 51 patients received oral buprenorphine tablets at 0.6-1.2 mg/d tid sublingually; 21 patients had 1.2-2.4 mg/d oral administration at q8h or q6h. Data data were analyzed statistically using t test and x~2 test. RESULTS: A total of 72 buprenorphine oral tablets were tested. The total effective rate, effective rate and effective rate of clinical analgesia were 91.67%, 86.11% and 5.56%, respectively. The effect of analgesia was better in the 21 high-dose group than in the low-dose group; the analgesic effect on bone metastases was poor. The main adverse reactions were sleepiness, dizziness, nausea, vomiting and headache; no drug tolerance or physical dependence was found within 2 weeks. Conclusion: The buprenorphine combined tablet has obvious analgesic effect on advanced cancer pain, long duration of efficacy, easy use, light adverse reactions, little addiction, and easy acceptance by patients. It has value in domestic development.